About us
Meet the Members of Our Pharmaceutical Research Company
Management and Board of Directors
Was a principal investigator and a senior research fellow at Edinburgh University’s Medical School. She has a long-standing interest in tissue remodeling and repair.
She was trained as a pharmacologist at Bradford University and SmithKline Beechams Cardiopulmonary Product Support Group. She then went on to receive further training and a Ph.D. in matrix remodeling and respiratory function at McGill University’s Meakins Christie Laboratories. She is the principal inventor of the research detailing the use of beta1 integrin in tissue repair and replicative senescence.
Bob Marchesani is president and principal consultant with Proventus Consulting LLC. This consulting company guides pharmaceutical and biotechnology companies in the oncology field on integrating prescriber, patient, and payer insights into the drug development process and the commercialization strategy to exceed business goals at launch and beyond.
Marchesani has 33 years of experience in the US and global pharmaceutical industry and has a comprehensive background in product development and brand strategy, international marketing, brand positioning and differentiation, launch strategy, and cross-functional/cross-geographical collaboration.
He demonstrated global brand building, launch excellence, and life-cycle management skills as global brand leader for ALIMTA® (pemetrexed), which achieved peak sales of $2.8 billion, excellent brand equity, and significance as Lilly’s top-selling product in 2014. He also demonstrated launch excellence, leveraging customer insights, and life-cycle management skills as a marketing leader on GEMZAR® (gemcitabine), which achieved peak sales of $1.7 billion in 2008.
And in his last role with Lilly, Marchesani demonstrated strategic product and brand development skills as global brand leader for Lilly’s VERZENIO® (abemaciclib), launched in 2017.
He is a member of the Board of Directors of Isofol Medical AB and a member of the board’s remuneration committee. Marchesani also serves as an adjunct MBA faculty member for the capstone strategy class and as an executive mentor in Butler University’s Lacy School of Business.
He earned an MBA in marketing and a bachelor’s degree in journalism and public relations. Marchesani is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He is active in community service and has served in volunteer leadership positions for several educational and community organizations.
https://www.linkedin.com/in/bobmarchesani/
Ian is Chief Medical Officer of Artios Pharma. Ian has a wealth of experience in the translational research and clinical development of medicines to treat cancer.
Prior to joining Artios, Ian has held leadership positions within the global clinical development organizations of both Eli Lilly and Company in the US, and AstraZeneca and has held academic and clinical positions in the University of Aberdeen. He served as Global Senior Medical Director within Lilly he led the worldwide clinical development, regulatory approval and subsequent commercialization of key successful breakthrough medicines for multiple indications. While at AstraZeneca, Ian led both early and late phase clinical development of several novel cancer therapeutics for both adult and pediatric indications.
Ian has served as reviewer for several oncology journals and sat on national grant awarding panels within the United States and the United Kingdom. Prior to joining the pharmaceutical industry Ian was a Clinical Lecturer in the University of Aberdeen where he led research projects evaluating novel methods of predicting and assessing early treatment response of cancer therapeutics.
Nigel has over 25 years experience of working in the city having been a director of Pharmaceutical research at ABN AMRO, First Vice President of Merrill Lynch European Healthcare Equity Research, a partner at Sudbrook Associates, a healthcare corporate advisory business, and a partner at WG Partners. He has a Ph.D. in pharmacology and has worked in the research laboratories of ICI (AstraZeneca) and Glaxo. In addition, he gained Sales and Marketing experience at Glaxo. Nigel has played an active role in a number of the leading corporate transactions, including a number of the major European sector mergers, IPO’s and capital raises.
Osama is a seasoned global executive with extensive expertise in business development, licensing, and M&A within the healthcare and pharmaceutical sectors. Currently, he serves as the Global Head of Business Development & Licensing (BD&L) and Mergers & Acquisitions (M&A) at Sandoz AG, a leading pharmaceutical company listed on the Swiss Stock Exchange. In this strategic role, Osama is responsible for defining and implementing a worldwide strategy to drive value through co-development agreements, licensing, product acquisitions, and divestments. His work is pivotal to the Transformation & Growth Management Team, where he contributes critical insights in business strategy, licensing, and operational planning.
Throughout his career, Osama has held influential leadership roles, including Vice President of Business Development and Alliance Management at HIKMA Pharmaceuticals (LSE) and Senior Director of Marketing Analytics and Business Insight at Abbott Laboratories (NYSE). He has also served in senior positions at globally recognized companies such as Amgen Inc. (NASDAQ) and Genentech (NYSE). His background reflects a strong track record of fostering strategic partnerships and navigating complex business landscapes to deliver growth and competitive advantage.
Osama’s academic foundation is equally robust, holding a Master of Business Administration alongside a Bachelor of Science in Medical Laboratory Technology and a Master of Science in Basic and Molecular Biology. His educational and career journey underscores a commitment to leveraging his scientific and business acumen to transform marketing strategies, enhance product planning, and drive innovation.
As a non-executive board member, Osama brings a unique blend of strategic vision, analytical rigor, and industry knowledge, making him an invaluable advisor for organizations seeking to navigate the evolving healthcare environment and capitalize on growth opportunities. His experience in both operational and strategic roles equips him to provide balanced, insightful governance and support in board decision-making.
Mark brings over 30 years of international leadership experience across biotechnology, global health and medical research. He has built start-ups (2 in biotech), led large, complex organizations through significant change and supported governments and transnational institutions with the development and implementation of policy. He also spent the early part of his career managing humanitarian responses in conflict zones across Africa.
Now he divides his time between a variety of Board roles, Trusteeships, consultancy assignments and mentorship of young entrepreneurs. He also sits on the Audit Committee of the EDCTP, a €2 Billion public-public partnership between Europe and Africa to accelerate the translation of health sector research to public health impact in sub-Saharan Africa.